Google AI ModeJun 10, 2026
Small interfering RNA (siRNA) therapies, like Alnylam Pharmaceuticals' Amvuttra (vutrisiran) , have revolutionized the rare disease landscape.
Loading…
AI summary
Amvuttra (vutrisiran) is an RNA interference therapy indicated for the treatment of ATTR cardiomyopathy and hereditary ATTR polyneuropathy in adults.
AI named Amvuttra from November 2025 to June 2026.
Question: What are the latest affordable advancements in biopharma for treating rare diseases?
Google AI ModeJun 10, 2026
Small interfering RNA (siRNA) therapies, like Alnylam Pharmaceuticals' Amvuttra (vutrisiran) , have revolutionized the rare disease landscape.
None of these answers cited amvuttra.com. AI leaned on agilent.com, aisuperior.com, and clinicaltrialsarena.com.
amvuttra.com 0%Other sites 100%
Excerpts where Amvuttra appeared in the AI's answer
Small interfering RNA (siRNA) therapies, like Alnylam Pharmaceuticals' Amvuttra (vutrisiran) , have revolutionized the rare disease landscape.
